Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Lipidology

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacl.2017.11.006PMID 29217412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• A large-scale, observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 2 diabetes—JDCP study 1

  2015cited by this paper
• Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

  2015cited by this paper
• Ezetimibe added to statin therapy after acute coronary syndromes

  2015cited by this paper
• 8. Cardiovascular Disease and Risk Management

  2014cited by this paper
• GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

  2014cited by this paper
• Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

  2013cited by this paper
• Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice

  2012cited by this paper
• GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

  2012cited by this paper
• Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS).

  2011cited by this paper
• Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

  2011cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study.

  2011cited by this paper
• Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.

  2010cited by this paper
• Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

  2010cited by this paper
• Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

  2010cited by this paper
• Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

  2010cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

  2008cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.

  2007cited by this paper
• Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

  2006cited by this paper
• Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice

  2006cited by this paper
• GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

  2005cited by this paper
• The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.

  2002cited by this paper
• Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.

  2001cited by this paper
• Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance

  2000cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets.

  1990cited by this paper
• Influence of endogenous hyperinsulinism on high density lipoprotein2 level in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance.

  1986cited by this paper

• GLP-1R Agonism Directly Improves the Pumping Capacity of Murine Collecting Lymphatic Vessels

  2025cites this paper
• Increased Cholesterol Interactions in the Active Conformational State of the Glucagon-Like Peptide-1 Receptor.

  2025cites this paper
• Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway

  2025cites this paper
• GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review

  2025cites this paper
• Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

  2025cites this paper
• Exploring Beyond Numeric Weight Loss: The Metabolic Effects of Semaglutide.

  2025cites this paper
• Approach to Lipid Management in the Patient with Diabetes.

  2025cites this paper
• Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction

  2024cites this paper
• The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia

  2024cites this paper
• A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure

  2024cites this paper
• Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China

  2024cites this paper
• Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.

  2024cites this paper
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

  2023cites this paper
• The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy

  2023cites this paper
• The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia

  2023cites this paper
• Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets

  2023cites this paper
• The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial

  2023cites this paper
• Acute Cholesterol-Lowering Effect of Exendin-4 inLdlr−/− and C57BL/6J Mice

  2022cites this paper
• Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling

  2022influential citation
• Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.

  2022cites this paper
• Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease.

  2022cites this paper
• Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• The Impact of Incretin-Based Medications on Lipid Metabolism

  2021cites this paper
• Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors

  2021cites this paper
• Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis

  2021cites this paper
• A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents

  2020cites this paper
• Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.

  2020cites this paper
• Small dense low-density lipoprotein-lowering agents

  2019cites this paper
• Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials

  2018cites this paper